Latest News and Press Releases
Want to stay updated on the latest news?
-
BERLIN, Germany and SEATTLE, Nov. 18, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN:DE000A0BVT96) and Abbott Molecular Inc. (Abbott) today have expand their non-exclusive strategic...
-
Key Figures (in EUR thousand) - Revenues: 1,831 in 9M 2008; (9M 2007: 1,809) - EBIT: -8,536 in 9M 2008; improved by 16% (9M 2007: -10,179) - Net loss: -8,147 in 9M 2008; reduced by 17% (9M...
-
-- Successfully qualified 17 PRESEPT clinical sites; 12 sites initiated -- Enrollment nearly 500 hundred subjects in first three months -- Expanded clinical site network to include first...
-
- Clinical study with patient cohorts from multiple clinical centers completed - All study endpoints met - PITX2 biomarker classifies patients into groups at high and low risk for...
-
BERLIN, Sept. 19, 2008 (GLOBE NEWSWIRE) -- Corrected Voting Rights Notification: In correction of the voting rights notification dated 10 September 2008 and released by Epigenomics AG on 11...
-
BERLIN, Sept. 11, 2008 (GLOBE NEWSWIRE) -- Voting Rights Notification: On 10 September 2008 Federated Investors Inc., Pittsburgh, PA, USA made the following notifications regarding the holding of...
-
-- Clinical study of over 500 patient samples well on track for completion in Q4 2008 -- Interim analysis representing approximately half of the cases demonstrates statistical...
-
BERLIN, Aug. 22, 2008 (GLOBE NEWSWIRE) -- Issuer: Epigenomics AG - ISIN DE000A0BVT96 - Kleine Prasidentenstr. 1 10178 Berlin Deutschland Voting Rights Notification: On 21 August 2008...
-
Key Figures (in EUR thousand) * Revenues: 1,511 in H1 2008; increased by 13% (H1 2007: 1,343) * EBIT: -5,888 in H1 2008; improved by 15% ...
-
BERLIN and SEATTLE, July 29, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard:ECX), a molecular diagnostics company focusing on the development and commercialization of products for...